Despite recent biomedical advances in detecting and treating glaucoma, it remains a leading cause of irreversible vision loss and a substantial public health problem in the US and worldwide. In this issue of JAMA Ophthalmology, Ehrlich and colleagues1 make an important contribution by providing updated estimates of the prevalence of glaucoma and vision-affecting glaucoma in the US using data from population-based studies, the National Health and Nutrition Examination Survey, medical claims, and 2022 population estimates from the US Census Bureau.